What is Jaguar Animal Health's operating income?

Jaguar Animal Health's total operating income in 2025 was -$45.91 million, based on the following breakdown: Total Gross Profit: $7.74 million Total Operating Expenses: $53.65 million

Jaguar Animal Health (JAGX) Financials

$2.71 -0.04 (-1.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.71 0.00 (0.00%)

As of 09/18/2026 07:59 PM Eastern

Compare

Annual Income Statements for Jaguar Animal Health

This table shows Jaguar Animal Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-17	-15	-22	-33	-45	-39	-53	-47	-41	-38	-54
Consolidated Net Income / (Loss)	-16	-15	-22	-32	-39	-34	-53	-48	-42	-39	-54
Net Income / (Loss) Continuing Operations	-16	-15	-22	-32	-39	-34	-53	-48	-42	-39	-54
Total Pre-Tax Income	-16	-15	-35	-32	-39	-34	-53	-48	-42	-39	-54
Total Operating Income	-12	-14	-34	-31	-29	-27	-41	-34	-34	-31	-46
Total Gross Profit	0.13	0.09	3.48	1.65	1.96	6.11	2.00	9.94	7.72	9.73	7.74
Total Revenue	0.26	0.14	4.36	4.42	5.78	9.39	4.34	12	9.76	12	12
Operating Revenue	0.26	0.14	4.36	4.42	5.78	9.39	4.34	12	9.76	12	12
Total Cost of Revenue	0.12	0.05	0.88	2.77	3.82	3.28	2.33	2.02	2.04	1.96	3.77
Operating Cost of Revenue	0.12	0.05	0.88	2.77	3.82	3.28	2.33	2.02	2.04	1.96	3.77
Total Operating Expenses	13	14	38	32	31	33	43	44	42	41	54
Selling, General & Admin Expense	5.34	5.98	11	12	14	14	17	18	17	16	19
Marketing Expense	0.77	0.49	3.08	9.83	6.94	6.61	8.89	8.84	6.46	7.69	9.24
Research & Development Expense	6.48	7.21	4.27	5.15	5.82	6.41	15	18	19	17	25
Impairment Charge	-	-	19	5.21	4.00	-	-	0.00	0.37	0.00	0.80
Total Other Income / (Expense), net	-3.82	-1.14	-0.99	-1.32	-9.58	-7.16	-12	-14	-7.61	-8.42	-8.09
Interest Expense	3.32	1.09	1.69	3.17	11	4.66	9.17	15	2.69	-1.01	1.87
Other Income / (Expense), net	-0.50	-0.04	0.70	1.85	1.09	-2.51	-2.72	0.93	-4.93	-9.43	-6.22
Income Tax Expense	-	-	-13	-	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock Dividends Declared	0.35	-	-	1.00	6.19	4.84	-	-	-	0.00	0.14
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	-	0.00	-0.01	-0.94	-0.60	-0.76	-0.56
Basic Earnings per Share	($2.70)	($1.35)	($7.59)	($153.27)	($9.01)	($3.00)	($88.22)	($36.18)	($2,678.17)	($130.69)	($22.97)
Weighted Average Basic Shares Outstanding	6.15M	10.95M	2.90M	209.73K	4.97M	12.88M	596.15K	1.31M	15.42K	294.53K	2.33M
Diluted Earnings per Share	($2.70)	($1.35)	($7.59)	($153.27)	($9.01)	($3.00)	($88.22)	($36.18)	($2,678.17)	($130.69)	($22.97)
Weighted Average Diluted Shares Outstanding	6.15M	10.95M	2.90M	209.73K	4.97M	12.88M	596.15K	1.31M	15.42K	294.53K	2.33M
Weighted Average Basic & Diluted Shares Outstanding	6.15M	10.95M	2.90M	209.73K	4.97M	38.64M	77.05M	13.86M	-	674.04K	2.40M

This table shows Jaguar Animal Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-9.17	-9.23	-9.49	-9.85	-9.92	-10	-10	-9.50	-23	-7.02	-13
Consolidated Net Income / (Loss)	-9.31	-9.37	-9.63	-10	-10	-11	-11	-9.65	-23	8.72	-13
Net Income / (Loss) Continuing Operations	-9.32	-9.37	-9.63	-10	-10	-11	-11	-9.65	-23	8.72	-13
Total Pre-Tax Income	-9.31	-9.37	-9.63	-10	-10	-11	-11	-9.65	-23	8.72	-13
Total Operating Income	-7.56	-8.22	-7.20	-7.26	-8.16	-9.42	-8.01	-7.24	-21	10	-7.60
Total Gross Profit	1.61	1.92	2.29	2.57	2.95	1.70	2.45	2.55	1.04	19	0.19
Total Revenue	2.30	2.35	2.72	3.11	3.51	2.21	2.98	3.08	3.24	20	1.23
Operating Revenue	2.30	2.35	2.72	3.11	3.51	2.21	2.98	3.08	3.24	20	1.23
Total Cost of Revenue	0.69	0.43	0.43	0.54	0.56	0.52	0.53	0.53	2.20	1.16	1.03
Operating Cost of Revenue	0.69	0.43	0.43	0.54	0.56	0.52	0.53	0.53	2.20	1.16	1.03
Total Operating Expenses	9.17	10	9.49	9.83	11	11	10	9.79	22	8.93	7.79
Selling, General & Admin Expense	3.81	4.38	4.31	3.78	3.86	4.90	4.73	4.13	4.89	4.11	4.45
Marketing Expense	1.53	1.44	1.52	2.01	2.72	2.49	2.47	2.00	2.28	0.90	0.01
Research & Development Expense	3.46	4.31	3.65	4.04	4.53	3.73	3.27	3.66	14	3.93	3.34
Impairment Charge	-	-	-	-	-	0.00	0.00	-	-	0.00	0.00
Total Other Income / (Expense), net	-1.74	-1.15	-2.43	-2.76	-2.08	-1.18	-2.55	-2.41	-1.95	-1.46	-5.21
Interest Expense	0.25	-0.63	-0.11	-0.16	-0.11	-0.06	1.81	0.01	0.11	1.33	3.67
Other Income / (Expense), net	-1.49	-1.79	-2.54	-2.92	-2.19	-1.23	-0.75	-2.40	-1.84	-0.13	-1.54
Income Tax Expense	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00	0.00
Other Gains / (Losses), net	-	-	-	-	-	-	0.00	-	-	-	0.00
Preferred Stock Dividends Declared	-	-	-	-	-	0.00	0.00	-	-	16	0.02
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.14	-0.14	-0.14	-0.17	-0.31	-0.13	-0.15	-0.15	-0.13	-0.13	-0.12
Basic Earnings per Share	($594.64)	($87.12)	($2.66)	($26.29)	($33.68)	($584.45)	($358.94)	($6.28)	($9.95)	($13.60)	($15.70)
Weighted Average Basic Shares Outstanding	15.42K	105.90K	3.57M	374.81K	294.53K	17.90K	28.99K	1.51M	2.33M	515.79K	809.12K
Diluted Earnings per Share	($594.64)	($87.12)	($2.66)	($26.29)	($33.68)	($584.45)	($358.94)	($6.28)	($9.95)	($13.60)	($15.70)
Weighted Average Diluted Shares Outstanding	15.42K	105.90K	3.57M	374.81K	294.53K	17.90K	28.99K	1.51M	2.33M	515.79K	809.12K
Weighted Average Basic & Diluted Shares Outstanding	0.00	295.47M	9.24M	11.80M	674.04K	0.00	2.17M	3.74M	2.40M	603.13K	5.17M

This table details how cash moves in and out of Jaguar Animal Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	6.85	-6.75	-12	-17	-18	4.21	8.96	-12	1.00	1.53	-0.17
Net Cash From Operating Activities	-14	-14	-9.82	-23	-20	-15	-35	-33	-33	-29	-24
Net Cash From Continuing Operating Activities	-14	-14	-9.82	-23	-20	-15	-35	-33	-33	-29	-24
Net Income / (Loss) Continuing Operations	-16	-15	-22	-32	-39	-34	-53	-49	-42	-39	-54
Consolidated Net Income / (Loss)	-16	-15	-22	-32	-39	-34	-53	-49	-42	-39	-54
Depreciation Expense	0.01	0.05	0.58	1.32	1.74	1.73	1.72	1.98	2.01	1.90	1.91
Amortization Expense	2.72	0.51	0.60	1.20	5.35	3.22	5.27	12	14	0.73	0.44
Non-Cash Adjustments To Reconcile Net Income	0.33	0.23	20	7.82	12	17	8.38	6.35	4.13	10	12
Changes in Operating Assets and Liabilities, net	-1.08	-0.43	-9.13	-0.93	-0.66	-3.47	2.27	-4.43	-11	-3.01	17
Net Cash From Investing Activities	-3.00	2.38	-1.56	-0.01	0.00	-0.01	-0.01	-1.68	0.00	-0.23	-0.04
Net Cash From Continuing Investing Activities	-3.00	2.38	-1.56	-0.01	0.00	-0.01	-0.01	-1.68	0.00	-0.23	-0.04
Purchase of Property, Plant & Equipment	-0.02	-0.10	-	-0.01	0.00	-0.01	-0.01	-0.08	0.00	-0.02	-0.04
Acquisitions	-	-	-1.56	-	-	-	-	-1.60	0.00	-0.22	0.00
Net Cash From Financing Activities	24	5.28	11	25	22	19	44	23	34	31	24
Net Cash From Continuing Financing Activities	24	1.46	-0.39	5.72	2.71	19	44	23	34	30	24
Payment of Dividends	-	-	-	-	-	-	-	0.00	1.23	0.00	0.00
Issuance of Debt	6.87	7.49	2.80	4.73	5.05	21	34	24	32	31	20
Issuance of Preferred Equity	-	-	-	-	0.00	-	-	0.00	0.61	0.00	2.38
Issuance of Common Equity	19	1.06	0.36	9.17	2.88	5.81	11	0.00	1.24	0.00	2.31
Other Financing Activities, net	0.01	-	-0.57	-	0.00	-1.01	0.78	-1.26	-0.95	-0.71	-0.70
Cash Interest Paid	0.17	-	0.23	-	0.14	0.76	0.03	0.02	0.04	0.01	0.02

This table details how cash moves in and out of Jaguar Animal Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	3.24	5.20	4.38	-2.78	-5.27	19	18	1.32	4.31	-14	22
Net Cash From Operating Activities	-7.45	-7.05	-8.17	-6.34	-7.83	-7.31	-6.20	-4.69	-5.49	8.83	-5.34
Net Cash From Continuing Operating Activities	-7.45	-7.05	-8.17	-6.34	-7.83	14	15	-4.69	-5.49	-7.70	20
Depreciation Expense	0.50	0.50	0.45	0.47	0.48	0.48	0.48	0.48	0.48	0.47	0.47
Amortization Expense	1.80	0.38	0.11	0.12	0.12	0.07	0.08	0.08	0.22	0.05	0.50
Non-Cash Adjustments To Reconcile Net Income	2.72	1.37	2.23	3.43	3.00	13	14	2.49	4.48	-6.88	18
Changes in Operating Assets and Liabilities, net	-3.33	-0.15	-1.24	-0.18	-1.44	1.32	0.62	2.05	13	-1.34	1.13
Net Cash From Financing Activities	11	12	13	3.53	2.83	4.97	2.66	6.26	9.79	-6.62	1.86
Net Cash From Continuing Financing Activities	11	11	13	3.53	2.83	4.97	2.66	7.60	9.79	-6.62	1.86
Other Financing Activities, net	-0.61	-0.22	-0.09	-0.22	-0.17	1.52	-1.90	-0.17	-0.17	-6.62	-0.12
Cash Interest Paid	0.01	0.01	0.00	0.00	-	0.01	0.00	0.01	0.01	0.12	-0.11

This table presents Jaguar Animal Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	12	3.56	44	41	36	43	53	47	51	53	38
Total Current Assets	8.45	2.56	3.80	8.15	9.52	18	28	22	28	32	20
Cash & Equivalents	7.70	0.95	0.52	2.57	3.50	8.09	17	5.47	6.47	8.00	0.97
Restricted Cash	-	0.51	0.24	-	0.39	-	-	-	-	0.00	6.86
Accounts Receivable	0.06	0.30	0.47	1.00	1.69	4.56	2.14	2.47	2.18	1.65	1.70
Inventories, net	0.23	0.41	2.07	3.34	2.13	2.78	4.90	7.02	9.19	10	8.60
Prepaid Expenses	0.32	0.30	0.50	1.24	1.26	2.36	4.34	7.36	10	12	2.22
Plant, Property, & Equipment, net	0.83	0.89	1.22	0.76	0.71	0.68	0.65	0.56	0.50	0.46	0.46
Total Noncurrent Assets	3.12	0.12	39	32	26	24	24	25	22	21	18
Intangible Assets	-	-	33	32	26	24	23	22	20	18	16
Other Noncurrent Operating Assets	0.12	0.12	-	0.42	0.15	0.04	1.53	2.14	2.19	2.28	1.49
Total Liabilities & Shareholders' Equity	12	3.56	44	41	36	43	53	47	51	53	38
Total Liabilities	8.01	6.02	26	27	16	26	41	49	46	44	57
Total Current Liabilities	3.91	4.19	15	27	15	13	15	30	14	20	41
Short-Term Debt	1.86	2.07	5.42	16	6.78	3.79	3.18	16	4.87	12	27
Accounts Payable	0.57	0.52	7.35	5.41	5.35	4.76	4.93	5.81	4.97	5.29	8.69
Accrued Expenses	0.80	0.58	2.20	4.94	2.92	4.49	7.12	8.17	3.80	1.91	4.17
Current Deferred Revenue	0.25	0.22	0.18	-	-	-	-	-	0.00	0.17	0.17
Other Current Liabilities	0.43	0.80	0.23	0.22	0.34	0.18	0.24	0.48	0.35	0.30	0.19
Total Noncurrent Liabilities	4.10	1.82	11	0.00	0.45	12	26	18	32	25	16
Long-Term Debt	4.10	1.82	11	-	0.45	12	25	18	31	24	15
Noncurrent Deferred Revenue	0.00	0.01	-	-	-	-	-	-	0.00	0.55	0.38
Other Noncurrent Operating Liabilities	-	-	-	-	-	0.00	0.92	0.73	0.89	0.69	0.89
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	18	12	-	-	-	0.00	2.49	0.00
Total Equity & Noncontrolling Interests	4.40	-2.45	17	5.38	11	17	12	-1.36	4.90	6.49	-19
Total Preferred & Common Equity	4.40	-2.45	17	5.38	11	17	12	-0.66	4.96	7.29	-17
Preferred Stock	0.00	0.00	-	-	1.71	0.00	0.00	0.00	0.00	0.00	2.49
Total Common Equity	4.40	-2.46	17	5.38	8.96	17	12	-0.66	4.96	7.29	-20
Common Stock	30	38	80	100	142	184	231	267	314	354	381
Retained Earnings	-26	-40	-62	-95	-133	-167	-219	-267	-308	-346	-400
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	-	0.00	-0.68	-0.65	-0.47	-0.83
Noncontrolling Interest	-	-	-	-	-	0.00	0.24	-0.70	-0.06	-0.79	-1.40

This table presents Jaguar Animal Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	45	55	61	58	51	48	49	37	34
Total Current Assets	22	34	40	37	30	28	29	20	18
Cash & Equivalents	3.23	12	16	13	5.69	2.21	3.53	7.28	3.79
Restricted Cash	-	-	-	-	-	-	0.00	2.79	2.80
Accounts Receivable	1.85	1.71	1.36	1.31	1.39	1.32	1.50	0.28	0.20
Inventories, net	8.38	9.02	9.56	9.67	11	11	11	7.82	7.32
Prepaid Expenses	8.61	11	13	12	13	14	14	2.05	3.43
Plant, Property, & Equipment, net	0.51	0.48	0.49	0.48	0.45	0.44	0.48	0.42	0.42
Total Noncurrent Assets	23	21	21	21	21	20	20	17	16
Intangible Assets	21	20	19	19	18	18	17	16	15
Other Noncurrent Operating Assets	1.84	1.56	1.45	2.40	2.56	2.38	2.30	1.25	1.16
Total Liabilities & Shareholders' Equity	45	55	61	58	51	48	49	37	34
Total Liabilities	44	41	42	43	48	41	45	53	29
Total Current Liabilities	12	18	19	20	28	29	36	41	25
Short-Term Debt	3.51	10	11	11	19	19	23	22	14
Accounts Payable	5.13	3.32	4.09	4.55	7.03	6.62	8.44	4.96	4.79
Accrued Expenses	3.29	3.46	3.34	3.30	2.10	3.60	4.18	3.75	4.71
Current Deferred Revenue	-	0.17	0.17	0.17	0.17	0.17	0.17	0.17	0.17
Other Current Liabilities	0.53	0.47	0.42	0.37	0.27	0.26	0.23	9.73	1.87
Total Noncurrent Liabilities	32	23	23	23	20	12	8.99	13	3.89
Long-Term Debt	31	22	22	22	18	11	7.65	11	1.73
Noncurrent Deferred Revenue	-	0.68	0.64	0.60	0.51	0.47	0.43	0.34	0.30
Other Noncurrent Operating Liabilities	0.35	0.87	0.81	0.75	1.00	0.96	0.92	1.09	1.87
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1.42	12	17	13	0.83	6.88	4.36	-16	4.92
Total Preferred & Common Equity	1.36	12	17	14	1.78	7.99	5.63	-14	6.62
Preferred Stock	0.00	0.00	0.00	0.00	0.00	2.49	2.49	0.00	0.00
Total Common Equity	1.36	12	17	14	1.78	5.50	3.14	-14	6.62
Common Stock	301	330	344	351	359	374	381	378	412
Retained Earnings	-299	-317	-327	-337	-357	-367	-377	-391	-404
Accumulated Other Comprehensive Income / (Loss)	-0.80	-0.46	-0.54	-0.69	-0.70	-0.72	-0.84	-1.24	-1.24
Noncontrolling Interest	0.06	-0.18	-0.33	-0.51	-0.95	-1.11	-1.27	-1.57	-1.69

This table displays calculated financial ratios and metrics derived from Jaguar Animal Health's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	8,124,923.00	12,340,464.00	90,836,710.00	70,429,267.00	56,678,288.00	92,694,407.00	48,211,717.00	145,236,699.00	50,755,589.00	11,798,288.00	3,735,846.00
DEI Adjusted Shares Outstanding	0.00	0.00	0.00	3.00	168.00	275.00	429.00	1,291.00	33,837.00	13,484.00	106,738.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	0.00	-11,047,019.00	-266,226.19	-140,538.18	-122,599.07	-36,757.55	-1,220.56	-2,854.64	-501.93
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-45.23%	2,981.61%	1.26%	30.77%	62.51%	-53.81%	175.80%	-18.36%	19.75%	-1.52%
EBITDA Growth	-23.68%	-27.89%	-147.61%	18.26%	21.49%	-16.52%	-50.57%	46.67%	-21.54%	-59.31%	-32.27%
EBIT Growth	-56.66%	-5.27%	-146.18%	13.65%	3.85%	-4.65%	-48.96%	22.89%	-17.12%	-2.67%	-29.47%
NOPAT Growth	-49.66%	-9.17%	-152.08%	10.00%	6.09%	7.95%	-52.77%	15.46%	0.36%	10.09%	-48.90%
Net Income Growth	-89.23%	9.56%	-49.10%	-46.33%	-19.89%	12.27%	-55.58%	7.99%	13.42%	6.32%	-37.57%
EPS Growth	16.67%	50.00%	-49.10%	-46.33%	94.12%	12.27%	-55.58%	7.99%	13.42%	6.32%	82.42%
Operating Cash Flow Growth	-157.61%	-0.68%	31.84%	-131.36%	10.00%	25.32%	-128.89%	5.34%	-0.42%	11.61%	19.39%
Free Cash Flow Firm Growth	0.00%	-1.30%	-479.14%	70.88%	1.77%	-23.25%	-30.50%	-6.50%	-12.93%	24.38%	51.20%
Invested Capital Growth	74.11%	91.53%	112,576.70%	-15.21%	-14.29%	5.89%	-9.14%	16.49%	27.93%	6.50%	-56.18%
Revenue Q/Q Growth	27.16%	-15.68%	53.13%	1.23%	-1.53%	100.83%	-48.84%	10.96%	-8.95%	11.54%	-2.33%
EBITDA Q/Q Growth	2.15%	3.82%	-101.58%	25.07%	-113.29%	44.67%	-24.19%	28.74%	-24.95%	-8.68%	-34.03%
EBIT Q/Q Growth	-23.94%	3.44%	-98.77%	24.25%	-66.85%	37.28%	-18.26%	15.81%	-9.64%	-3.33%	-32.34%
NOPAT Q/Q Growth	-19.14%	3.75%	-102.89%	21.76%	17.84%	2.41%	-16.17%	11.67%	-3.85%	-1.98%	-39.87%
Net Income Q/Q Growth	-15.30%	2.99%	-304.00%	19.03%	37.80%	-136.79%	-11.79%	11.17%	-2.64%	-2.41%	-31.58%
EPS Q/Q Growth	-50.00%	0.00%	-304.00%	19.03%	21.52%	-136.79%	-11.79%	11.17%	-2.64%	-2.41%	13.74%
Operating Cash Flow Q/Q Growth	-16.16%	7.70%	-36.04%	1.85%	7.93%	-6.42%	-16.15%	7.02%	-3.19%	-1.29%	8.98%
Free Cash Flow Firm Q/Q Growth	0.00%	15.32%	1.69%	-9.31%	-9.94%	-100.18%	41.19%	-72.44%	-0.96%	-0.19%	39.17%
Invested Capital Q/Q Growth	35.02%	-102.45%	-30.38%	-19.94%	-4.31%	59.28%	-35.88%	8.16%	4.36%	2.98%	-49.34%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	52.22%	63.28%	79.81%	37.37%	33.92%	65.05%	46.18%	83.11%	79.13%	83.27%	67.21%
EBITDA Margin	-3,955.85%	-9,236.38%	-742.16%	-599.10%	-359.69%	-257.89%	-840.65%	-162.55%	-242.00%	-321.95%	-432.42%
Operating Margin	-4,816.67%	-9,599.84%	-785.27%	-697.98%	-501.26%	-283.93%	-939.05%	-287.85%	-351.31%	-263.76%	-398.82%
EBIT Margin	-5,010.81%	-9,630.37%	-769.33%	-656.07%	-482.37%	-310.63%	-1,001.75%	-280.07%	-401.76%	-344.47%	-452.88%
Profit (Net Income) Margin	-6,305.24%	-10,410.87%	-503.73%	-727.92%	-667.34%	-360.25%	-1,213.38%	-404.78%	-429.27%	-335.79%	-469.09%
Tax Burden Percent	100.17%	100.00%	62.50%	100.00%	100.03%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	125.62%	108.10%	104.76%	110.95%	138.31%	115.97%	121.13%	144.53%	106.85%	97.48%	103.58%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-145.83%	-70.97%	-78.22%	-75.77%	-117.92%	-96.73%	-78.58%	-60.96%	-122.37%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-123.65%	-175.84%	-672.98%	-386.57%	-368.03%	-220.38%	-140.78%	-123.03%	-192.63%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	-150.90%	-87.20%	-90.56%	-95.49%	-244.15%	-825.34%	-2,288.03%	-504.78%	1,234.68%
Return on Equity (ROE)	-939.33%	-1,515.11%	-296.74%	-158.17%	-168.78%	-171.26%	-362.07%	-922.07%	-2,366.62%	-565.74%	1,112.31%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-172.94%	-54.50%	-62.83%	-81.49%	-108.35%	-111.96%	-103.09%	-67.26%	-44.25%
Operating Return on Assets (OROA)	-153.90%	-170.70%	-142.19%	-68.44%	-71.93%	-73.57%	-90.37%	-66.49%	-79.86%	-77.29%	-113.64%
Return on Assets (ROA)	-193.66%	-184.54%	-93.10%	-75.93%	-99.52%	-85.32%	-109.46%	-96.10%	-85.33%	-75.35%	-117.71%
Return on Common Equity (ROCE)	1,038.82%	-1,514.02%	-296.61%	-88.09%	-53.01%	-113.47%	-359.01%	-962.22%	-2,876.57%	-499.28%	1,430.80%
Return on Equity Simple (ROE_SIMPLE)	-370.34%	600.35%	-127.27%	-597.16%	-361.09%	-196.59%	-453.02%	0.00%	-844.61%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-8.71	-9.51	-24	-22	-20	-19	-28	-24	-24	-22	-32
NOPAT Margin	-3,371.67%	-6,719.89%	-549.69%	-488.59%	-350.88%	-198.75%	-657.34%	-201.49%	-245.91%	-184.63%	-279.17%
Net Nonoperating Expense Percent (NNEP)	-294.44%	-450.37%	-22.18%	104.87%	594.76%	310.80%	250.11%	123.65%	62.20%	62.07%	70.26%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-58.89%	-51.34%	-134.83%
Cost of Revenue to Revenue	47.78%	36.72%	20.19%	62.63%	66.08%	34.95%	53.82%	16.89%	20.87%	16.73%	32.79%
SG&A Expenses to Revenue	2,066.46%	4,227.75%	257.90%	278.01%	233.80%	153.30%	394.53%	149.45%	169.94%	139.71%	161.97%
R&D to Revenue	2,506.32%	5,092.36%	97.90%	116.73%	100.78%	68.33%	347.84%	147.60%	190.51%	141.52%	216.89%
Operating Expenses to Revenue	4,868.89%	9,663.12%	865.08%	735.36%	535.19%	348.98%	985.24%	370.96%	430.44%	347.04%	466.03%
Earnings before Interest and Taxes (EBIT)	-13	-14	-34	-29	-28	-29	-43	-33	-39	-40	-52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-10	-13	-32	-26	-21	-24	-36	-19	-24	-38	-50
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.16	0.00	0.74	2.99	5.07	4.39	4.32	0.00	1.55	1.64	0.00
Price to Tangible Book Value (P/TBV)	4.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	70.75	62.43	2.91	3.65	7.86	8.05	11.57	1.06	0.79	1.02	0.30
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.86	1.71	2.60	3.30	2.67	1.50	1.08	1.13	2.45
Enterprise Value to Revenue (EV/Rev)	64.00	79.57	6.50	10.79	10.75	8.91	14.20	3.35	3.79	3.52	3.41
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.35	-1.58	0.95	0.69	0.32	0.94	2.38	-24.80	7.32	3.96	-2.28
Long-Term Debt to Equity	0.93	-0.74	0.64	0.00	0.02	0.72	2.11	-13.09	6.33	2.62	-0.81
Financial Leverage	-1.48	-1.19	1.22	0.50	0.13	0.25	0.66	3.75	16.25	4.10	-6.41
Leverage Ratio	4.85	8.21	3.19	2.08	1.70	2.01	3.31	9.59	27.74	7.51	-9.45
Compound Leverage Factor	6.09	8.88	3.34	2.31	2.35	2.33	4.01	13.87	29.64	7.32	-9.79
Debt to Total Capital	57.51%	271.26%	48.73%	40.75%	24.50%	48.52%	70.41%	104.20%	87.98%	79.83%	178.41%
Short-Term Debt to Total Capital	17.95%	144.43%	16.11%	40.75%	22.97%	11.34%	7.95%	49.22%	11.94%	27.04%	115.12%
Long-Term Debt to Total Capital	39.56%	126.83%	32.62%	0.00%	1.53%	37.18%	62.46%	54.98%	76.04%	52.79%	63.28%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	5.80%	0.00%	0.00%	0.00%	0.00%	0.00%	10.43%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	45.61%	39.34%	0.00%	0.60%	-2.17%	-0.16%	3.81%	-5.87%
Common Equity to Total Capital	42.50%	-171.36%	51.26%	13.64%	30.37%	51.47%	28.98%	-2.04%	12.17%	16.36%	-82.96%
Debt to EBITDA	-0.58	-0.30	-0.51	-0.61	-0.35	-0.67	-0.77	-1.73	-1.52	-0.94	-0.85
Net Debt to EBITDA	0.17	-0.19	-0.48	-0.51	-0.16	-0.34	-0.31	-1.45	-1.24	-0.73	-0.70
Long-Term Debt to EBITDA	-0.40	-0.14	-0.34	0.00	-0.02	-0.51	-0.69	-0.91	-1.31	-0.62	-0.30
Debt to NOPAT	-0.68	-0.41	-0.68	-0.75	-0.36	-0.87	-0.99	-1.40	-1.49	-1.65	-1.32
Net Debt to NOPAT	0.20	-0.26	-0.65	-0.63	-0.17	-0.44	-0.39	-1.17	-1.22	-1.28	-1.08
Long-Term Debt to NOPAT	-0.47	-0.19	-0.46	0.00	-0.02	-0.67	-0.88	-0.74	-1.29	-1.09	-0.47
Altman Z-Score	-4.51	-28.14	-4.47	-5.63	-5.96	-5.58	-7.36	-10.00	-10.43	-10.91	-19.40
Noncontrolling Interest Sharing Ratio	210.59%	0.07%	0.04%	44.30%	68.59%	33.74%	0.85%	-4.35%	-21.55%	11.75%	-28.63%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.16	0.61	0.25	0.31	0.62	1.35	1.84	0.74	2.00	1.63	0.50
Quick Ratio	1.98	0.30	0.06	0.13	0.34	0.96	1.24	0.26	0.62	0.49	0.07
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-9.70	-9.83	-57	-17	-16	-20	-26	-28	-31	-24	-12
Operating Cash Flow to CapEx	-530,217.15%	-13,831.81%	0.00%	-348,258.50%	0.00%	-218,257.14%	-582,833.33%	-42,992.21%	0.00%	-183,650.00%	-57,770.73%
Free Cash Flow to Firm to Interest Expense	-2.92	-8.99	-33.74	-5.22	-1.53	-4.31	-2.85	-1.87	-11.73	0.00	-6.23
Operating Cash Flow to Interest Expense	-4.32	-13.18	-5.83	-7.16	-1.92	-3.28	-3.81	-2.22	-12.38	0.00	-12.69
Operating Cash Flow Less CapEx to Interest Expense	-4.32	-13.28	-5.83	-7.17	-1.92	-3.28	-3.81	-2.23	-12.38	0.00	-12.72
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.03	0.02	0.18	0.10	0.15	0.24	0.09	0.24	0.20	0.22	0.25
Accounts Receivable Turnover	0.00	0.78	11.27	6.00	4.28	3.00	1.29	5.19	4.20	6.10	6.88
Inventory Turnover	0.58	0.16	0.71	1.02	1.39	1.34	0.61	0.34	0.25	0.20	0.40
Fixed Asset Turnover	0.30	0.17	4.14	4.45	7.85	13.53	6.53	19.81	18.54	24.35	24.84
Accounts Payable Turnover	0.19	0.10	0.22	0.43	0.71	0.65	0.48	0.38	0.38	0.38	0.54
Days Sales Outstanding (DSO)	0.00	468.98	32.37	60.78	85.19	121.61	282.23	70.38	86.96	59.81	53.03
Days Inventory Outstanding (DIO)	632.54	2,256.84	515.24	357.31	261.66	273.25	600.93	1,077.83	1,452.56	1,823.51	916.08
Days Payable Outstanding (DPO)	1,881.48	3,833.12	1,631.78	842.59	514.90	562.58	757.85	970.53	965.99	957.77	675.65
Cash Conversion Cycle (CCC)	-1,248.94	-1,107.30	-1,084.17	-424.49	-168.05	-167.71	125.31	177.68	573.54	925.54	293.46
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.35	-0.03	33	28	24	25	23	27	34	37	16
Invested Capital Turnover	-0.31	-0.76	0.27	0.15	0.22	0.38	0.18	0.48	0.32	0.33	0.44
Increase / (Decrease) in Invested Capital	0.99	0.32	33	-5.01	-3.99	1.41	-2.31	3.79	7.49	2.23	-21
Enterprise Value (EV)	17	11	28	48	62	84	62	40	37	41	39
Market Capitalization	18	8.84	13	16	45	76	50	13	7.68	12	3.48
Book Value per Share	$0.54	($0.20)	$0.19	$0.08	$0.16	$0.19	$0.24	$0.00	$0.10	$0.62	($5.29)
Tangible Book Value per Share	$0.54	($0.20)	($0.24)	($0.37)	($0.30)	($0.08)	($0.23)	($0.16)	($0.30)	($0.95)	($9.58)
Total Capital	10	1.43	34	39	30	33	40	32	41	45	24
Total Debt	5.95	3.89	16	16	7.23	16	28	34	36	36	43
Total Long-Term Debt	4.10	1.82	11	0.00	0.45	12	25	18	31	24	15
Net Debt	-1.74	2.42	16	14	3.35	8.12	11	28	29	28	35
Capital Expenditures (CapEx)	0.00	0.10	0.00	0.01	0.00	0.01	0.01	0.08	0.00	0.02	0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.29	-1.03	-6.92	-4.99	-2.98	0.27	-0.90	2.40	12	17	-0.70
Debt-free Net Working Capital (DFNWC)	6.40	0.43	-6.16	-2.42	0.91	8.36	16	7.87	19	25	7.13
Net Working Capital (NWC)	4.55	-1.64	-12	-19	-5.87	4.57	13	-8.02	14	12	-20
Net Nonoperating Expense (NNE)	7.58	5.22	-2.00	11	18	15	24	24	18	18	22
Net Nonoperating Obligations (NNO)	-4.74	2.42	16	4.51	1.63	8.12	11	28	29	28	35
Total Depreciation and Amortization (D&A)	2.73	0.56	1.18	2.52	7.09	4.95	6.98	14	16	2.63	2.36
Debt-free, Cash-free Net Working Capital to Revenue	-500.65%	-728.09%	-158.76%	-113.05%	-51.52%	2.89%	-20.85%	20.04%	126.77%	141.42%	-6.09%
Debt-free Net Working Capital to Revenue	2,478.49%	305.15%	-141.34%	-54.89%	15.72%	89.09%	372.48%	65.78%	193.04%	209.87%	61.95%
Net Working Capital to Revenue	1,759.44%	-1,157.28%	-265.68%	-419.12%	-101.65%	48.72%	299.03%	-67.06%	143.18%	106.89%	-176.43%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($38,272,500.00)	($19,136,250.00)	($7,229,250.00)	($2,069,550.00)	($121,635.00)	($13,500.00)	($5,310.00)	($2,170.80)	($2,685.00)	($4,574.15)	($803.95)
Adjusted Weighted Average Basic Shares Outstanding	1.00	1.00	0.00	0.00	4.60K	9.63K	9.94K	21.86K	15.38K	8.42K	66.64K
Adjusted Diluted Earnings per Share	($38,272,500.00)	($19,136,250.00)	($7,229,250.00)	($2,069,550.00)	($121,635.00)	($13,500.00)	($5,310.00)	($2,170.80)	($2,685.00)	($4,574.15)	($803.95)
Adjusted Weighted Average Diluted Shares Outstanding	1.00	1.00	0.00	0.00	4.60K	9.63K	9.94K	21.86K	15.38K	8.42K	66.64K
Adjusted Basic & Diluted Earnings per Share	($38,272,500.00)	($19,136,250.00)	($7,229,250.00)	($2,069,550.00)	($121,635.00)	($13,500.00)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	1.00	3.00	16.00	368.00	2.86K	17.12K	231.04K	0.00	19.26K	68.59K
Normalized Net Operating Profit after Tax (NOPAT)	-8.71	-9.51	-11	-18	-17	-19	-28	-24	-24	-22	-32
Normalized NOPAT Margin	-3,371.67%	-6,719.89%	-242.69%	-405.99%	-294.53%	-198.75%	-657.34%	-201.49%	-243.25%	-184.63%	-274.31%
Pre Tax Income Margin	-6,294.69%	-10,410.87%	-805.97%	-727.92%	-667.17%	-360.25%	-1,213.38%	-404.78%	-429.27%	-335.79%	-469.09%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-3.90	-12.46	-19.89	-9.13	-2.61	-6.26	-4.73	-2.25	-14.61	0.00	-27.94
NOPAT to Interest Expense	-2.63	-8.70	-14.21	-6.80	-1.90	-4.01	-3.11	-1.62	-8.94	0.00	-17.22
EBIT Less CapEx to Interest Expense	-3.90	-12.56	-19.89	-9.13	-2.61	-6.26	-4.73	-2.25	-14.61	0.00	-27.96
NOPAT Less CapEx to Interest Expense	-2.63	-8.79	-14.21	-6.80	-1.90	-4.01	-3.11	-1.62	-8.94	0.00	-17.24
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.94%	0.00%	0.00%
Augmented Payout Ratio	-2.56%	0.00%	-2.53%	0.00%	-0.17%	0.00%	0.00%	0.00%	2.94%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Jaguar Animal Health's official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	50,755,589.00	50,755,589.00	295,474,346.00	9,241,231.00	11,798,288.00	674,043.00	0.00	2,174,850.00	3,735,846.00	2,400,765.00	603,134.00
DEI Adjusted Shares Outstanding	33,837.00	33,837.00	196,983.00	369,649.00	13,484.00	19,258.00	0.00	2,174,850.00	106,738.00	68,593.00	603,134.00
DEI Earnings Per Adjusted Shares Outstanding	-271.01	-272.66	-48.19	-26.66	-735.69	-543.36	0.00	-4.37	-217.37	-102.27	-21.06
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-29.45%	19.22%	1.68%	10.49%	52.57%	-5.83%	9.48%	-0.80%	-7.81%	815.63%	-58.88%
EBITDA Growth	-232.48%	-8.85%	-79.59%	-182.89%	-44.54%	-10.84%	10.68%	5.24%	-129.60%	204.59%	0.41%
EBIT Growth	-61.61%	1.98%	-9.84%	8.27%	-14.34%	-6.50%	10.10%	5.31%	-123.16%	194.35%	-4.39%
NOPAT Growth	-20.22%	16.56%	11.17%	17.36%	-7.94%	-14.68%	-11.25%	0.33%	-160.41%	254.40%	5.12%
Net Income Growth	-13.08%	24.43%	21.67%	-26.78%	-9.94%	-13.11%	-9.68%	3.72%	-126.63%	182.32%	-21.23%
EPS Growth	-13.08%	24.43%	21.67%	-26.78%	-9.94%	-13.11%	-9.68%	76.11%	70.46%	182.32%	95.63%
Operating Cash Flow Growth	-16.01%	29.14%	9.78%	6.61%	-5.03%	-3.79%	24.17%	26.05%	29.87%	220.73%	13.83%
Free Cash Flow Firm Growth	-55.91%	-27.34%	-54.96%	45.95%	37.85%	53.41%	72.19%	84.48%	171.10%	673.97%	504.92%
Invested Capital Growth	27.93%	31.32%	29.04%	7.93%	6.50%	-0.16%	-5.44%	-10.92%	-56.18%	-78.85%	-59.13%
Revenue Q/Q Growth	-18.24%	2.22%	15.74%	14.22%	12.90%	-36.91%	34.55%	3.49%	4.93%	526.65%	-93.96%
EBITDA Q/Q Growth	-99.06%	-35.16%	-0.65%	-4.47%	-1.71%	-3.64%	18.89%	-10.83%	-146.43%	147.21%	-177.23%
EBIT Q/Q Growth	18.50%	-10.56%	2.66%	-4.59%	-1.58%	-2.98%	17.83%	-10.16%	-139.41%	143.54%	-190.92%
NOPAT Q/Q Growth	14.00%	-8.71%	12.39%	-0.90%	-12.32%	-15.50%	15.01%	9.60%	-193.48%	168.48%	-152.23%
Net Income Q/Q Growth	-17.78%	-0.63%	-2.78%	-4.08%	-2.13%	-3.54%	0.34%	8.64%	-140.39%	137.61%	-246.76%
EPS Q/Q Growth	-17.78%	-0.63%	-2.78%	-4.08%	-2.13%	-3.54%	0.34%	38.79%	-58.44%	137.61%	-15.44%
Operating Cash Flow Q/Q Growth	-9.73%	5.42%	-15.94%	22.39%	-23.42%	6.54%	15.30%	24.29%	-17.04%	260.90%	-160.45%
Free Cash Flow Firm Q/Q Growth	10.19%	-9.87%	6.49%	41.43%	-3.27%	17.64%	44.19%	67.30%	572.99%	564.87%	-60.63%
Invested Capital Q/Q Growth	4.36%	1.33%	3.45%	-1.34%	2.98%	-5.01%	-2.03%	-7.06%	-49.34%	-54.16%	89.34%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	70.13%	81.71%	84.31%	82.59%	84.13%	76.74%	82.31%	82.74%	31.99%	94.29%	15.84%
EBITDA Margin	-293.30%	-387.84%	-337.27%	-308.46%	-277.89%	-456.46%	-275.16%	-294.68%	-692.06%	52.14%	-666.37%
Operating Margin	-328.57%	-349.43%	-264.50%	-233.66%	-232.46%	-425.52%	-268.78%	-234.77%	-656.63%	50.23%	-620.16%
EBIT Margin	-393.35%	-425.44%	-357.81%	-327.64%	-294.78%	-481.12%	-293.82%	-312.75%	-713.57%	49.58%	-745.88%
Profit (Net Income) Margin	-404.74%	-398.47%	-353.84%	-322.43%	-291.65%	-478.59%	-354.48%	-312.94%	-716.94%	43.03%	-1,045.06%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	102.90%	93.66%	98.89%	98.41%	98.94%	99.47%	120.64%	100.06%	100.47%	86.80%	140.11%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-73.50%	-81.05%	-59.12%	-50.18%	-53.73%	-99.11%	-63.55%	-57.77%	-201.48%	70.68%	-504.41%
ROIC Less NNEP Spread (ROIC-NNEP)	-87.47%	-99.49%	-82.71%	-69.42%	-69.62%	-114.56%	-86.08%	-77.22%	-228.23%	65.32%	-545.90%
Return on Net Nonoperating Assets (RNNOA)	-1,421.50%	-177.75%	-129.28%	-209.58%	-285.63%	-336.93%	-145.95%	-182.41%	1,462.84%	-286.05%	-1,668.84%
Return on Equity (ROE)	-1,495.00%	-258.80%	-188.40%	-259.76%	-339.36%	-436.04%	-209.50%	-240.19%	1,261.36%	-215.37%	-2,173.26%
Cash Return on Invested Capital (CROIC)	-103.09%	-101.79%	-95.04%	-69.58%	-67.26%	-64.44%	-60.17%	-56.98%	-44.25%	42.55%	8.23%
Operating Return on Assets (OROA)	-78.19%	-76.82%	-64.14%	-66.13%	-66.14%	-104.03%	-63.25%	-68.29%	-179.05%	32.98%	-503.18%
Return on Assets (ROA)	-80.45%	-71.95%	-63.43%	-65.08%	-65.44%	-103.49%	-76.31%	-68.34%	-179.90%	28.63%	-705.01%
Return on Common Equity (ROCE)	-1,817.14%	-227.98%	-170.63%	-228.79%	-299.49%	-341.05%	-180.96%	-201.79%	1,622.53%	-214.66%	-2,231.63%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-323.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-5.29	-5.75	-5.04	-5.08	-5.71	-6.59	-5.60	-5.07	-15	10	-5.32
NOPAT Margin	-230.00%	-244.60%	-185.15%	-163.56%	-162.72%	-297.86%	-188.15%	-164.34%	-459.64%	50.23%	-434.11%
Net Nonoperating Expense Percent (NNEP)	13.97%	18.44%	23.60%	19.24%	15.89%	15.44%	22.53%	19.45%	26.75%	5.36%	41.49%
Return On Investment Capital (ROIC_SIMPLE)	-12.98%	-13.09%	-10.18%	-10.99%	-13.58%	-17.40%	-15.49%	-14.43%	-62.38%	58.52%	-25.97%
Cost of Revenue to Revenue	29.87%	18.29%	15.69%	17.41%	15.87%	23.26%	17.69%	17.26%	68.01%	5.71%	84.16%
SG&A Expenses to Revenue	165.43%	186.35%	158.54%	121.49%	110.00%	221.18%	158.68%	134.09%	151.04%	20.26%	363.27%
R&D to Revenue	150.57%	183.41%	134.25%	130.08%	129.21%	168.47%	109.60%	118.65%	442.44%	19.38%	272.33%
Operating Expenses to Revenue	398.70%	431.14%	348.81%	316.25%	316.59%	502.26%	351.09%	317.52%	688.62%	44.06%	636.00%
Earnings before Interest and Taxes (EBIT)	-9.05	-10	-9.74	-10	-10	-11	-8.75	-9.64	-23	10	-9.14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.75	-9.12	-9.18	-9.59	-9.75	-10	-8.20	-9.09	-22	11	-8.16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.55	0.38	1.04	0.92	1.64	1.80	0.46	1.61	0.00	0.00	0.27
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.79	0.45	1.73	1.19	1.02	0.28	0.22	0.43	0.30	0.05	0.07
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.08	0.79	1.02	0.97	1.13	1.04	0.91	1.06	2.45	3.12	0.65
Enterprise Value to Revenue (EV/Rev)	3.79	2.69	3.60	3.28	3.52	3.13	2.63	2.84	3.41	0.77	0.33
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.56	4.61
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	7.32	2.25	1.73	2.13	3.96	11.18	4.26	7.06	-2.28	-2.10	3.16
Long-Term Debt to Equity	6.33	1.52	1.14	1.39	2.62	5.56	1.56	1.75	-0.81	-0.70	0.35
Financial Leverage	16.25	1.79	1.56	3.02	4.10	2.94	1.70	2.36	-6.41	-4.38	3.06
Leverage Ratio	27.74	5.11	4.57	6.11	7.51	6.06	4.23	5.41	-9.45	-7.15	6.99
Compound Leverage Factor	28.54	4.79	4.51	6.01	7.43	6.03	5.10	5.42	-9.49	-6.20	9.79
Debt to Total Capital	87.98%	69.19%	63.33%	68.02%	79.83%	91.79%	80.99%	87.59%	178.41%	190.53%	75.97%
Short-Term Debt to Total Capital	11.94%	22.39%	21.38%	23.57%	27.04%	46.15%	51.31%	65.81%	115.12%	126.88%	67.54%
Long-Term Debt to Total Capital	76.04%	46.79%	41.96%	44.45%	52.79%	45.64%	29.68%	21.78%	63.28%	63.65%	8.43%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.87%	7.08%	10.43%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.16%	4.97%	4.15%	4.04%	3.81%	3.80%	-3.06%	-3.61%	-5.87%	-9.05%	-8.27%
Common Equity to Total Capital	12.17%	25.85%	32.52%	27.93%	16.36%	4.41%	15.20%	8.95%	-82.96%	-81.48%	32.30%
Debt to EBITDA	-1.52	-1.32	-1.16	-0.96	-0.94	-0.96	-0.78	-0.83	-0.85	-1.14	-0.54
Net Debt to EBITDA	-1.24	-0.84	-0.59	-0.57	-0.73	-0.81	-0.72	-0.73	-0.70	-0.79	-0.31
Long-Term Debt to EBITDA	-1.31	-0.89	-0.77	-0.63	-0.62	-0.48	-0.29	-0.21	-0.30	-0.38	-0.06
Debt to NOPAT	-1.49	-1.40	-1.48	-1.57	-1.65	-1.65	-1.27	-1.34	-1.32	-1.80	-0.86
Net Debt to NOPAT	-1.22	-0.89	-0.76	-0.94	-1.28	-1.40	-1.18	-1.19	-1.08	-1.25	-0.49
Long-Term Debt to NOPAT	-1.29	-0.95	-0.98	-1.02	-1.09	-0.82	-0.47	-0.33	-0.47	-0.60	-0.10
Altman Z-Score	-8.47	-8.02	-7.14	-7.94	-9.06	-10.08	-11.00	-11.17	-16.90	-13.59	-16.84
Noncontrolling Interest Sharing Ratio	-21.55%	11.91%	9.43%	11.92%	11.75%	21.78%	13.62%	15.99%	-28.63%	0.33%	-2.69%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.00	1.89	2.10	1.84	1.63	1.08	0.96	0.81	0.50	0.50	0.69
Quick Ratio	0.62	0.75	0.91	0.73	0.49	0.25	0.12	0.14	0.07	0.19	0.16
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-13	-14	-13	-7.69	-7.94	-6.54	-3.65	-1.19	5.65	38	15
Operating Cash Flow to CapEx	0.00%	0.00%	-51,062.50%	0.00%	0.00%	0.00%	0.00%	-8,683.33%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-51.52	0.00	0.00	0.00	0.00	0.00	-2.02	-198.93	51.79	28.29	4.03
Operating Cash Flow to Interest Expense	-30.04	0.00	0.00	0.00	0.00	0.00	-3.43	-781.50	-50.35	6.65	-1.46
Operating Cash Flow Less CapEx to Interest Expense	-30.04	0.00	0.00	0.00	0.00	0.00	-3.43	-790.50	-50.23	6.65	-1.46
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.20	0.18	0.18	0.20	0.22	0.22	0.22	0.22	0.25	0.67	0.67
Accounts Receivable Turnover	4.20	6.42	6.97	6.65	6.10	7.45	8.81	8.39	6.88	35.43	36.74
Inventory Turnover	0.25	0.24	0.23	0.23	0.20	0.21	0.21	0.21	0.40	0.48	0.55
Fixed Asset Turnover	18.54	19.79	20.09	21.24	24.35	24.68	25.43	24.58	24.84	67.59	64.84
Accounts Payable Turnover	0.38	0.47	0.47	0.43	0.38	0.39	0.40	0.33	0.54	0.74	0.86
Days Sales Outstanding (DSO)	86.96	56.84	52.36	54.87	59.81	49.02	41.41	43.52	53.03	10.30	9.93
Days Inventory Outstanding (DIO)	1,452.56	1,522.61	1,580.25	1,580.18	1,823.51	1,751.19	1,729.06	1,738.67	916.08	759.17	668.85
Days Payable Outstanding (DPO)	965.99	775.07	776.47	847.73	957.77	925.74	913.35	1,112.90	675.65	495.19	423.15
Cash Conversion Cycle (CCC)	573.54	804.38	856.14	787.32	925.54	874.48	857.12	669.29	293.46	274.28	255.63
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	34	35	36	35	37	35	34	32	16	7.34	14
Invested Capital Turnover	0.32	0.33	0.32	0.31	0.33	0.33	0.34	0.35	0.44	1.41	1.16
Increase / (Decrease) in Invested Capital	7.49	8.29	8.09	2.61	2.23	-0.06	-1.96	-3.87	-21	-27	-20
Enterprise Value (EV)	37	27	37	34	41	36	31	34	39	23	9.08
Market Capitalization	7.68	4.56	18	12	12	3.21	2.56	5.07	3.48	1.38	1.81
Book Value per Share	$0.10	$0.24	$0.06	$1.47	$0.62	$0.15	$189.80	$1.44	($5.29)	($3.80)	$10.97
Tangible Book Value per Share	($0.30)	($0.15)	($0.01)	($0.58)	($0.95)	($1.38)	($415.33)	($6.50)	($9.58)	($7.96)	($14.04)
Total Capital	41	46	52	49	45	40	36	35	24	17	20
Total Debt	36	32	33	33	36	37	29	31	43	33	16
Total Long-Term Debt	31	22	22	22	24	18	11	7.65	15	11	1.73
Net Debt	29	20	17	20	28	31	27	27	35	23	8.97
Capital Expenditures (CapEx)	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.05	-0.01	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	12	15	16	15	17	15	15	13	-0.70	-8.46	-0.60
Debt-free Net Working Capital (DFNWC)	19	26	32	28	25	21	17	16	7.13	1.60	5.99
Net Working Capital (NWC)	14	16	21	17	12	2.23	-1.32	-6.72	-20	-20	-7.85
Net Nonoperating Expense (NNE)	4.02	3.62	4.59	4.94	4.52	4.00	4.96	4.58	8.32	1.46	7.48
Net Nonoperating Obligations (NNO)	29	20	17	20	28	31	27	27	35	23	8.97
Total Depreciation and Amortization (D&A)	2.30	0.88	0.56	0.60	0.59	0.55	0.56	0.56	0.70	0.52	0.97
Debt-free, Cash-free Net Working Capital to Revenue	126.77%	144.21%	157.53%	143.01%	141.42%	131.38%	127.43%	109.13%	-6.09%	-28.62%	-2.17%
Debt-free Net Working Capital to Revenue	193.04%	259.31%	315.10%	269.62%	209.87%	180.64%	146.12%	139.06%	61.95%	5.41%	21.52%
Net Working Capital to Revenue	143.18%	156.80%	205.97%	160.01%	106.89%	19.31%	-11.13%	-57.02%	-176.43%	-69.25%	-28.21%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($891,960.00)	($90.00)	($101.00)	($26.25)	($29,470.00)	($584.50)	($359.10)	($6.28)	($348.25)	($13.60)	($15.70)
Adjusted Weighted Average Basic Shares Outstanding	10.00	105.90K	93.98K	374.81K	337.00	17.90K	28.99K	1.51M	66.64K	515.79K	809.12K
Adjusted Diluted Earnings per Share	($891,960.00)	($90.00)	($101.00)	($26.25)	($29,470.00)	($584.50)	($359.10)	($6.28)	($348.25)	($13.60)	($15.70)
Adjusted Weighted Average Diluted Shares Outstanding	10.00	105.90K	93.98K	374.81K	337.00	17.90K	28.99K	1.51M	66.64K	515.79K	809.12K
Adjusted Basic & Diluted Earnings per Share	($891,960.00)	$0.00	$0.00	$0.00	($29,470.00)	$0.00	$0.00	$0.00	($348.25)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	196.98K	369.65K	471.93K	770.00	0.00	62.14K	3.74M	68.59K	603.13K	5.17M
Normalized Net Operating Profit after Tax (NOPAT)	-5.29	-5.75	-5.04	-5.08	-5.71	-6.59	-5.60	-5.07	-15	7.13	-5.32
Normalized NOPAT Margin	-230.00%	-244.60%	-185.15%	-163.56%	-162.72%	-297.86%	-188.15%	-164.34%	-459.64%	35.16%	-434.11%
Pre Tax Income Margin	-404.74%	-398.47%	-353.84%	-322.43%	-291.65%	-478.59%	-354.48%	-312.94%	-716.94%	43.03%	-1,045.06%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-36.48	0.00	0.00	0.00	0.00	0.00	-4.84	-1,607.00	-211.78	7.57	-2.49
NOPAT to Interest Expense	-21.33	0.00	0.00	0.00	0.00	0.00	-3.10	-844.43	-136.42	7.67	-1.45
EBIT Less CapEx to Interest Expense	-36.48	0.00	0.00	0.00	0.00	0.00	-4.84	-1,616.00	-211.66	7.57	-2.49
NOPAT Less CapEx to Interest Expense	-21.33	0.00	0.00	0.00	0.00	0.00	-3.10	-853.43	-136.30	7.67	-1.45
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	2.94%	0.00%	-0.04%	0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	2.94%	0.00%	-0.04%	0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Jaguar Health’s Q2 2026 results show a sharp deterioration from the prior quarter’s unusually high revenue, while the company remains dependent on financing to support ongoing operations. Revenue fell to $1.2 million from $20.3 million in Q1 2026 and $3.2 million in Q4 2025. The Q1 figure appears to have included a significant nonrecurring or unusual revenue contribution, making the sequential decline especially pronounced.

Gross profit dropped to $194,000, producing a gross margin of approximately 15.8%, compared with roughly 94.3% in Q1. Operating expenses totaled $7.8 million, including $4.5 million of selling, general and administrative costs and $3.3 million of research and development spending. As a result, operating loss was $7.6 million and net loss attributable to common shareholders was $12.7 million, or $15.70 per reported basic share.

Cash flow remains challenging. Jaguar reported negative operating cash flow of $5.3 million in Q2 2026, following positive reported operating cash flow of $8.8 million in Q1 and negative operating cash flow in each quarter of 2024 and most of 2025. The Q2 cash-flow statement also reports $20.3 million of cash from continuing operating activities, which does not reconcile with total operating cash flow and should be treated cautiously when assessing liquidity.

At June 30, 2026, the company had $3.8 million of unrestricted cash and $2.8 million of restricted cash. Total current assets of $17.5 million were below current liabilities of $25.4 million, implying a current ratio of approximately 0.69. Although total liabilities declined from $53.2 million in Q1 2026 to $29.3 million in Q2, the balance sheet remains highly leveraged relative to the company’s revenue base. Total equity and noncontrolling interests were only $4.9 million.

Lower total liabilities: Total liabilities fell to $29.3 million in Q2 2026 from $53.2 million in Q1 2026 and $45.1 million in Q3 2025, improving the balance sheet compared with the recent peak.
Reduced operating expenses versus late 2025: Q2 operating expenses of $7.8 million were substantially below the $22.3 million reported in Q4 2025, primarily because of lower marketing and research and development spending.
Lower short-term debt sequentially: Short-term debt declined to $13.8 million from $22.1 million in Q1 2026, while long-term debt also fell to $1.7 million from $11.1 million.
Limited capital spending: Property, plant and equipment totaled only $417,000, indicating that near-term cash needs are driven mainly by operating losses and working capital rather than heavy capital expenditures.
Revenue remains volatile: Quarterly revenue increased from $2.3 million in Q4 2023 to $3.5 million in Q4 2024, but remained near $2 million to $3 million during much of 2025 before spiking to $20.3 million in Q1 2026 and falling back to $1.2 million in Q2.
Large noncash adjustments: Q2 operating cash flow included $18.2 million of noncash adjustments, meaning reported cash generation was heavily influenced by accounting adjustments rather than recurring earnings.
Persistent operating losses: Jaguar has reported operating losses in most of the supplied quarters. Q2 2026’s $7.6 million operating loss was more than six times revenue.
Sharp gross-margin compression: Gross margin declined from approximately 94% in Q1 2026 to 16% in Q2, suggesting that the latest revenue mix was considerably less profitable.
Ongoing cash burn: Negative operating cash flow was reported in Q2 2026 and across the majority of the 2024–2025 periods, increasing the company’s need for additional borrowing or equity financing.
Liquidity and dilution risk: Unrestricted cash of $3.8 million was small relative to quarterly operating expenses, while common stock increased substantially over the period and accumulated retained earnings were negative $403.7 million. Future financing could dilute existing shareholders further.

Overall, the financial statements present a high-risk profile. The reduction in debt and operating expenses is encouraging, but it is outweighed by volatile revenue, weak gross margins, recurring losses, negative operating cash flow and limited unrestricted liquidity. Investors should focus on whether Jaguar can produce consistent commercial revenue and positive operating cash flow without relying on additional debt or equity issuance.

09/20/26 11:24 AM ETAI Generated. May Contain Errors.

Jaguar Animal Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Jaguar Animal Health's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Jaguar Animal Health's net income appears to be on an upward trend, with a most recent value of -$54.00 million in 2025, rising from -$16.29 million in 2015. The previous period was -$39.25 million in 2024. Check out Jaguar Animal Health's forecast to explore projected trends and price targets.

Jaguar Animal Health's total operating income in 2025 was -$45.91 million, based on the following breakdown:

Total Gross Profit: $7.74 million
Total Operating Expenses: $53.65 million

Over the last 10 years, Jaguar Animal Health's total revenue changed from $258.38 thousand in 2015 to $11.51 million in 2025, a change of 4,355.0%.

Jaguar Animal Health's total liabilities were at $57.01 million at the end of 2025, a 28.3% increase from 2024, and a 612.1% increase since 2015.

In the past 10 years, Jaguar Animal Health's cash and equivalents has ranged from $520.70 thousand in 2017 to $17.05 million in 2021, and is currently $968 thousand as of their latest financial filing in 2025.

Over the last 10 years, Jaguar Animal Health's book value per share changed from 0.54 in 2015 to -5.29 in 2025, a change of -1,077.7%.

Related Companies

Financial statements for NASDAQ:JAGX last updated on 9/17/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jaguar Animal Health (JAGX) Financials

Financials Breakdown Chart

Key Financial Trends

Jaguar Animal Health Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jaguar Animal Health (JAGX) Financials

Annual Income Statements for Jaguar Animal Health

Quarterly Income Statements for Jaguar Animal Health

Annual Cash Flow Statements for Jaguar Animal Health

Quarterly Cash Flow Statements for Jaguar Animal Health

Annual Balance Sheets for Jaguar Animal Health

Quarterly Balance Sheets for Jaguar Animal Health

Annual Metrics And Ratios for Jaguar Animal Health

Quarterly Metrics And Ratios for Jaguar Animal Health

Financials Breakdown Chart

Key Financial Trends

Jaguar Animal Health Financials - Frequently Asked Questions

When does Jaguar Animal Health's financial year end?

How has Jaguar Animal Health's net income changed over the last 10 years?

What is Jaguar Animal Health's operating income?

How has Jaguar Animal Health's revenue changed over the last 10 years?

How much debt does Jaguar Animal Health have?

How much cash does Jaguar Animal Health have?

How has Jaguar Animal Health's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools